Control Bionics secures FDA registration for NeuroStrip™ wearable platform
Control Bionics Limited (ASX: CBL) has confirmed that its NeuroStrip™ surface EMG (sEMG) wearable platform is now registered and listed with the United States Food and Drug Administration (FDA) as a medical device. The step formally establishes NeuroStrip within the US medical device regulatory framework.
Announced on 4 August 2026, the registration carries FDA listing number D605008 and registration number 3006789226.
The credential opens engagement across one of the world’s largest and most influential healthcare markets, reinforcing NeuroStrip’s commercial positioning as the company scales the platform into new applications.
When big ASX news breaks, our subscribers know first
What the FDA registration means for commercial engagement
The registration reinforces NeuroStrip’s credentials as a medical-grade device. It is not a prerequisite for the platform’s existing use in sports performance and general rehabilitation, but it adds further stature in commercial discussions with existing and prospective customers across all verticals.
Where recognised US regulatory status matters most is in advanced clinical rehabilitation, medical research applications, and prospective human-computer interface and medtech development partners. In these settings, the company notes that recognised US regulatory status is typically a threshold condition of engagement.
The NeuroStrip commercial expansion across elite sports, clinical rehabilitation, and Apple BCI integration was already progressing through structured evaluation programs with AFL clubs, NRL clubs, and Ohio University before this regulatory milestone was secured.
| Application Area | Registration Required? | How FDA Listing Helps |
|---|---|---|
| Sports Performance | No | Adds stature and medical-grade credibility in commercial discussions |
| Everyday Rehabilitation | No | Reinforces device credentials without changing existing rollout |
| Advanced Clinical Rehabilitation | Typically a threshold condition | Meets baseline regulatory expectations for provider engagement |
| Medical Research & HCI/Medtech Partnerships | Typically a threshold condition | Provides the recognised US regulatory foundation partners expect |
Understanding surface EMG and why regulatory status matters
Surface EMG (sEMG) is a non-invasive technology that captures the electrical activity generated by muscles. It requires no surgery or implantation. Control Bionics converts these physiological signals into what the company describes as “measurable, decision-ready outcomes.”
For investors, the significance is practical. In medical and research markets, formal regulatory recognition is often a baseline requirement before customers and partners will engage. On that basis, the FDA listing acts to unlock doors rather than to generate immediate revenue.
The single underlying platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. A recognised regulatory foundation strengthens the platform’s credibility across each of these areas as adoption deepens.
A broader multi-jurisdiction regulatory push
The FDA listing is one building block within a wider regulatory strategy. Control Bionics has also submitted applications for regulatory approval in additional key jurisdictions.
The pending applications include:
-
TGA registration in Australia (Therapeutic Goods Administration)
-
CE marking under the EU Medical Device Regulation (MDR)
-
Registration under the UK MDR framework
These remain pending applications. The company has cautioned that there is no certainty as to the timing or ultimate outcome of any pending regulatory application, and readers should not place undue reliance on forward-looking statements.
The German reimbursement listing secured earlier in 2026 illustrates how regulatory achievements at the country level translate into commercial opportunity for Control Bionics, converting approval into funded access through statutory health insurance and accelerating distributor negotiations across the DACH region.
Control Bionics frames the pace of these submissions as a reflection of its 25 year plus legacy as an innovative medtech business, as it continues to scale NeuroStrip into new markets and deepen adoption with existing partners.
Management perspective
Jeremy Steele, CEO and Managing Director
“This FDA registration is an important milestone for Control Bionics and for NeuroStrip… formal recognition under the US medical device framework meaningfully strengthens our position in advanced clinical rehabilitation, medical research and future human-computer interface applications, where customers and partners expect a recognised regulatory foundation.”
Steele added that the credential supports the company’s strategy to accelerate growth across all three NeuroStrip application areas: performance, rehabilitation, and research and data.
What it means for investors
The FDA registration lowers a key barrier to engaging high-value clinical, research and medtech partners in the US market, where recognised regulatory status is often a baseline requirement for engagement.
It supports the company’s stated strategy to scale NeuroStrip into new markets and deepen adoption with existing partners, adding medical-grade credibility across each of the platform’s application areas.
For those tracking the story, the near-term catalyst watch centres on the outcomes of the pending TGA, CE marking and UK MDR applications. The company has flagged no certainty as to their timing or ultimate outcome, leaving these regulatory milestones as the next signposts to monitor as Control Bionics advances its multi-jurisdiction strategy.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done. Over 20,000 active subscribers stay ahead of the market with real-time alerts the moment announcements hit. Click the “Free Alerts” button at StockWire X to join them today.